argenx, a global immunology company focused on improving the lives of individuals with severe autoimmune diseases, has announced that it will be hosting a conference call and audio webcast on May 9, 2024, at 2:30 PM CET to discuss its first quarter financial results and provide a business update. The webcast can be accessed on the Investors section of the argenx website. A replay of the webcast will be available for approximately one year after the presentation.
Dial-in numbers for the call are provided for participants from various countries, with an access code required to join the call. It is recommended to dial in 15 minutes before the scheduled start time to ensure a smooth connection.
argenx specializes in translating immunology breakthroughs into novel antibody-based medicines through its Immunology Innovation Program (IIP). The company has developed and commercialized the first approved neonatal Fc receptor (FcRn) blocker in several countries. Currently, argenx is evaluating efgartigimod in multiple serious autoimmune diseases and progressing experimental medicines within its therapeutic franchises.
For more information about argenx, including its portfolio of medicines and ongoing research, visit the company’s website and follow their social media accounts. For media inquiries, please contact Ben Petok, and for investor relations, contact Alexandra Roy for the US and Lynn Elton for the EU.